CompletedNCT00128479
Mifepristone for psychotic depression: safety and early effects
About this title
Read the official source —Researchers compared mifepristone, mifepristone 600 mg, mifepristone 1200 mg and placebo, tracking side effects to assess safety in people with depression.
Medication studyAges 18–75United States
Understand this study
What did researchers investigate?
Researchers compared mifepristone, mifepristone 600 mg, mifepristone 1200 mg and placebo, tracking side effects to assess safety in people with depression.
Who was this study for?
This study was for people with depression. Listed age limits: 18 years to 75 years. Other eligibility criteria applied.
- Listed locations
- Little Rock and 43 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateSeptember 2004
- Recruitment status
- Completed
- Enrollment listed in the registry
- 443
- Sponsor
- Corcept Therapeutics
- Sponsor type
- Biotech company
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States
- Age range
- From 18 Years to 75 Years
- Official registry ID
- NCT00128479
- Official title
Show the full official title
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Safety and Efficacy of Three Dose Levels of CORLUX™ (Mifepristone) Plus an Antidepressant vs. Placebo Plus an Antidepressant in the Treatment of Psychotic Symptoms in Patients With Major Depressive Disorder With Psychotic Features (PMD)
Get this study by email
Recruitment & locations
CompletedLittle Rock · Cerritos · Fountain Valley
40 more locations
- National City
- Oceanside
- Riverside
- Torrance
- Westminster
- Hamden
- Washington D.C.
- Fort Lauderdale
- Jacksonville
- Miami
- North Miami
- Sebring
- Tampa
- Honolulu
- Oakbrook Terrace
- Schaumburg
- Skokie
- Prairie Village
- Lake Charles
- New Orleans
- Shreveport
- Saint Charles
- St Louis
- Albuquerque
- Brooklyn
- Elmsford
- Staten Island
- The Bronx
- Cleveland
- Middleburg Heights
- Oklahoma City
- Moon Township
- Philadelphia
- Charleston
- Johnson City
- Dallas
- DeSoto
- Houston
- Lake Jackson
- Seattle
Questions about this study
What did researchers investigate?
Researchers compared mifepristone, mifepristone 600 mg, mifepristone 1200 mg and placebo, tracking side effects to assess safety in people with depression.
Who is behind this study?
The study sponsor is Corcept Therapeutics.
Did this study involve medication?
Yes. The study involved medication, including mifepristone, mifepristone matched placebo, mifepristone 600 mg and mifepristone 1200 mg.
Who was this study for?
This study was for people with depression. Listed age limits: 18 years to 75 years. Other eligibility criteria applied.
